About
Wells Pharmacy Network is a privately held compounding pharmacy operating both a 20,500 square foot 503A facility and a 20,000 square foot FDA-registered 503B outsourcing facility. The company specializes in personalized medications across wellness, hormone therapy, sexual health, dermatology, weight management, thyroid support, and adrenal health. Their approach centers on tailoring formulations to individual patient needs rather than offering standardized solutions.
The company serves both direct consumers and healthcare providers through multiple delivery methods including oral capsules, topical creams, sublingual options, and injectables. Their product portfolio includes bioidentical hormone replacement therapy (BHRT) pellets, which the company notes are recognized throughout the industry, alongside customized formulations for specific health concerns like hormonal imbalances, sexual wellness, skin health, and hair loss. They also offer branded products like Niagen Plus in both IV and at-home injectable forms.
Wells Pharmacy Network positions itself on operational rigor and clinical collaboration. The company adheres to USP standards and FDA guidance for both sterile and non-sterile compounding, maintains pharmacist consultation availability, and works directly with healthcare providers to develop treatment plans. Most prescriptions ship within three business days, with options for standard, expedited, and overnight delivery including cold chain shipping for temperature-sensitive products.
Longevity Contribution
- Dual facility operation: 503A compounding pharmacy and FDA-registered 503B outsourcing facility allowing bulk medication dispensing for physician office use
- Industry recognition for implantable BHRT pellets with documented customer support infrastructure
- Rapid turnaround: most orders shipped within 3 business days with multiple shipping options including cold chain logistics
- Licensed in most U.S. states with direct pharmacist consultation available for formulation customization and ingredient compatibility assessment